PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
The mechanism involves oxidation of the selenol of a selenocysteine residue by hydrogen peroxide. This process gives the derivative with a selenenic acid (RSeOH) group. The selenenic acid is then converted back to the selenol by a two step process that begins with reaction with glutathione (GSH) to form the GS-SeR and water. A second GSH molecule reduces the GS-SeR intermediate back to the selenol, releasing glutathione disulfide (GS-SG) as the by-product. A simplified representation is shown below:
=== Familial hypercholesterolemia === The 1985 Nobel Prize for medicine went to two researchers for their work related to familial hypercholesterolemia, which causes large and rapid increases in cholesterol levels. Their research led to the development of statin drugs which are now commonly used to treat high cholesterol.
==== Crosstalk ==== Many known phosphorylation sites and O-GlcNAcylation sites are nearby each other or overlapping. As protein O-GlcNAcylation and phosphorylation both occur on serine and threonine residues, these post-translational modifications can regulate each other. For example, in CKIIα, S347 O-GlcNAc has been shown to antagonize T344 phosphorylation. Reciprocal inhibition, i.e., phosphorylation inhibition of O-GlcNAcylation and O-GlcNAcylation of phosphorylation, has been observed on other proteins including murine estrogen receptor β, RNA Pol II, tau, p53, CaMKIV, p65, β-catenin, and α-synuclein. Positive cooperativity has also been observed between these two post-translational modifications, i.e., phosphorylation induces O-GlcNAcylation or O-GlcNAcylation induces phosphorylation. This has been demonstrated on MeCP2 and HDAC1. In other proteins, e.g., cofilin, phosphorylation and O-GlcNAcylation appear to occur independently of each other. In some cases, therapeutic strategies are under investigation to modulate O-GlcNAcylation to have a downstream effect on phosphorylation. For instance, elevating tau O-GlcNAcylation may offer therapeutic benefit by inhibiting pathological tau hyperphosphorylation. Besides phosphorylation, O-GlcNAc has been found to influence other post-translational modifications such as lysine acetylation and monoubiquitination.
In a hierarchy, individuals are either dominant or submissive. A despotic hierarchy is where one individual is dominant while the others are submissive, as in wolves and lemurs, and a pecking order is a linear ranking of individuals where there is a top individual and a bottom individual. Pecking orders may also be ranked by sex, where the lowest individual of a sex has a higher ranking than the top individual of the other sex, as in hyenas. Dominant individuals, or alphas, have a high chance of reproductive success, especially in harems where one or a few males (resident males) have exclusive breeding rights to females in a group. Non-resident males can also be accepted in harems, but some species, such as the common vampire bat (Desmodus rotundus), may be more strict. Some mammals are perfectly monogamous, meaning that they mate for life and take no other partners (even after the original mate's death), as with wolves, Eurasian beavers, and otters. There are three types of polygamy: either one or multiple dominant males have breeding rights (polygyny), multiple males that females mate with (polyandry), or multiple males have exclusive relations with multiple females (polygynandry). It is much more common for polygynous mating to happen, which, excluding leks, are estimated to occur in up to 90% of mammals. Lek mating occurs when males congregate around females and try to attract them with various courtship displays and vocalizations, as in harbor seals. All higher mammals (excluding monotremes) share two major adaptations for care of the young: live birth and lactation.
Sources: en.wikipedia.org
=== Russia === Russia has a plan for increasing its fleet of fast breeder reactors significantly. A BN-800 reactor (800 MWe) at Beloyarsk was completed in 2012, succeeding a smaller BN-600. It reached its full power production in 2016. Plans for the construction of a larger BN-1200 reactor (1,200 MWe) was scheduled for completion in 2018, with two additional BN-1200 reactors built by the end of 2030. However, in 2015 Rosenergoatom postponed construction indefinitely to allow fuel design to be improved after more experience of operating the BN-800 reactor, and among cost concerns. In January 2026, Rosatom reported that preparations had begun for Beloyarsk Unit 5, using the BN-1200M sodium-cooled fast reactor. Construction of the lead-cooled BREST-OD-300 reactor at the Siberian Chemical Combine in Seversk began in June 2021. The BREST (Russian: bystry reaktor so svintsovym teplonositelem, English: fast reactor with lead coolant) design is seen as a successor to the BN series and the 300 MWe unit at the SCC could be the forerunner to a 1,200 MWe version for wide deployment as a commercial power generation unit. The development program is as part of an Advanced Nuclear Technologies Federal Program 2010–2020 that seeks to exploit fast reactors for uranium efficiency while 'burning' radioactive substances that would otherwise be disposed of as waste. Its core would measure about 2.3 metres in diameter by 1.1 metres in height and contain 16 tonnes of fuel. The unit would be refuelled every year, with each fuel element spending five years in total within the core.
A drug carrier or drug vehicle is a substrate used in the process of drug delivery which serves to improve the selectivity, effectiveness, and/or safety of drug administration. Drug carriers are primarily used to control the release of drugs into systemic circulation. This can be accomplished either by slow release of a particular drug over a long period of time (typically diffusion) or by triggered release at the drug's target by some stimulus, such as changes in pH, application of heat, and activation by light. Drug carriers are also used to improve the pharmacokinetic properties, specifically the bioavailability, of many drugs with poor water solubility and/or membrane permeability. A wide variety of drug carrier systems have been developed and studied, each of which has unique advantages and disadvantages. Some of the more popular types of drug carriers include liposomes, polymeric micelles, microspheres, and nanoparticles. Different methods of attaching the drug to the carrier have been implemented, including adsorption, integration into the bulk structure, encapsulation, and covalent bonding. Different types of drug carrier utilize different methods of attachment, and some carriers can even implement a variety of attachment methods.
A NATO spokesperson said, "discussions among NATO allies on the framework [Trump] referenced will focus on ensuring Arctic security through the collective efforts of allies, especially the seven Arctic allies". Greenland prime minister Jens-Frederik Nielsen emphasised that "nobody else than Greenland and the Kingdom of Denmark have the mandate to make deals or agreements about Greenland and the Kingdom of Denmark". Trump's comments in Davos were described as a great climbdown. Reuters reported that his reversal of policy followed pressure by his own aides opposing an invasion of Greenland. Former American NATO ambassador R. Nicholas Burns said Trump had clearly backed down in the face of tough military, economic, and political resistance from the Europeans that the Trump administration had not calculated. Trump's behaviour during 2025 and 2026 was described as having damaged the United States standing in the world and how allies see the nation in the long term, while resulting in no other outcome than maintaining Greenland's status quo. CNN reported that no actual document exists yet and that the information available indicates that the supposed deal "sounds a lot like what the United States already had", and described the affair as "one of the most erratic episodes involving a modern president on the world stage". Greenlandic politician Tillie Martinussen said: "We can never really trust America again." Trump's reversal was widely referred to as a TACO moment. The New York Times argued that it showed the "limits of his coercive powers".
== Use == The Weimaraner is a versatile hunting dog, and may be used to track, point to, flush or retrieve birds or other game. Registration is subject to successful completion of a working trial. In Germany it is not considered to be suitable for keeping as a companion dog. According to the breed club, it "... basically belongs in the hands of hunters due to its development and its characteristics ... It is not a companion dog, but a hunting dog through and through. As such, it needs work in practical hunting in order to preserve its balanced nature"; whelps are placed mainly with hunters.
Pfizer Inc. ( FY-zər) is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer and Charles F. Erhart, Pfizer is one of the oldest pharmaceutical companies in North America. Pfizer develops and produces medication and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company's largest products by sales are Eliquis (apixaban) ($7.9 billion in 2025 revenues, 13% of total revenues), Prevnar (a pneumococcal conjugate vaccine) ($6.5 billion in 2025 revenues, 10% of total revenues), Paxlovid (Nirmatrelvir/ritonavir) ($2.4 billion in 2025 revenues, 4% of total revenues), Vyndaqel (tafamidis) ($6.4 billion in 2025 revenues, 10% of total revenues), Comirnaty (the Pfizer–BioNTech COVID-19 vaccine) ($4.4 billion in 2025 revenues, 7% of total revenues), and Ibrance (palbociclib) ($4.1 billion in 2025 revenues, 7% of total revenues). In 2025, 59% of the company's revenues came from the United States, 5% came from China, and 36% came from other countries. The company is ranked fifth on the list of largest biomedical companies by revenue. It is ranked the 69th on the Fortune 500 and 73rd on the Forbes Global 2000.
Sources: en.wikipedia.org
In the late 1990s, the World Trade Organization authorized the United States and Canada to impose retaliatory tariffs of US$116.8 million per year on the European Union after it found the EU beef hormone ban to be in violation of the WTO Agreement on the Application of Sanitary and Phytosanitary Measures (SPS Agreement). In September 2009, the trade representatives from the US and EU signed a memorandum of understanding, which established a new duty-free import quota in the European Union for grain-fed, high-quality beef as part of a compromise solution.
=== 3 June === A missile strike on Dnipro killed a two-year-old girl and wounded 22 people after it hit a two-story building. Five of them were reportedly children, seventeen people were hospitalized and several were believed to have been trapped under the rubble. Belgorod Oblast Governor Vyacheslav Gladkov said that two people were killed by Ukrainian shelling.
=== Organic reactions === Hydrogen peroxide is frequently used as an oxidizing agent. Illustrative is oxidation of thioethers to form sulfoxides, such as conversion of thioanisole to methyl phenyl sulfoxide:
== Northern Hemisphere == In the Northern Hemisphere, there are two towns in Sakha, Russia that compete for the title of "Pole of Cold". These are Verkhoyansk (located at 67°33′N 133°23′E, altitude 127 metres (417 ft)) and Oymyakon (located at 63°15′N 143°9′E, altitude 745 metres (2,444 ft)). However, the World Meteorological Organization has recognized in 2020 a temperature of −69.6 °C (−93.3 °F), measured near the topographic summit of the Greenland Ice Sheet on 22 December 1991, as the lowest in the Northern Hemisphere. The record was measured at an automatic weather station and was uncovered after nearly 30 years. In December 1868 and then in February 1869 Ivan Khudyakov made the discovery of the Northern Pole of Cold by measuring a record temperature of −63.2 °C (−81.8 °F) in Verkhoyansk. Later, on January 15, 1885, a temperature of −67.8 °C (−90.0 °F) was registered there by Sergey Kovalik. This measurement was published in the Annals of the General Physical Observatory in 1892; by mistake it was written as −69.8 °C (−93.6 °F), which was later corrected. One can still find this incorrect value in some literature. The coldest reliably measured temperature in Verkhoyansk was −67.8 °C (−90.0 °F) on February 5 and 7 of 1892. On February 6, 1933, a temperature of −67.7 °C (−89.9 °F) was recorded at Oymyakon's weather station. At the time, this was the coldest reliably measured temperature for the Northern Hemisphere. The weather station is in a valley between Oymyakon and Tomtor.
Another emerging and promising application of freeze casting is the production of porous foams for green hydrogen generation through advanced thermochemical processes like Chemical Loop Combustion (CLC) and the Steam Iron Process (SIP). These processes leverage the unique properties of porous metal structures, such as optimized reaction kinetics, enhanced thermal efficiency, and sustainability. In Chemical Loop Combustion (CLC), foams made from materials like iron oxides act as oxygen carriers, enabling fuel combustion without direct air contact, separating CO2 for capture while producing high-purity hydrogen. Similarly, in Steam Iron Process (SIP), dendritic pore structures ensure efficient water vapor distribution and maximize hydrogen yield. The precise control over porosity and thermal properties afforded by freeze casting, along with the use of eco-friendly solvents like camphene, positions these foams as a vital innovation for scalable and sustainable hydrogen production, contributing to the fight against climate change.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.